I've been following the federal marijuana rescheduling proceedings closely, and I think it's worth discussing what these developments could mean for patients. In my own practice, I've recommended medical cannabis to some patients for symptom relief, and I've heard many report positive experiences. Those experiences are encouraging, but we still need more rigorous clinical research to understand which patients benefit most and which products are most appropriate.
This might be hot take, but marijuana isn't beneficial for everyone. I've seen situations where patients with psychotic disorders, including schizophrenia, may experience worsening symptoms, including hallucinations. THC can exacerbate psychosis in susceptible individuals, which is an important reason to approach cannabis thoughtfully, consider a patient's medical and psychiatric history, and recognize that it isn't an appropriate option for everyone.
As a physician who works with patients through Texas's Compassionate Use Program, I've spent the last several years helping patients navigate medical cannabis and understand their options within the existing legal framework.
Personally, I support broader legalization—even if it eventually means my services is no longer needed. I realize that might sound counterintuitive coming from someone who operates a medical cannabis clinic, but I believe healthcare should ultimately serve patients, not preserve a particular business model. If patients can eventually access appropriate products safely, affordably, and without unnecessary barriers, I'd consider that progress, even if it fundamentally changes the role of clinics like mine.
As of October 2026, the broader proposal to move marijuana from Schedule I to Schedule III remains unresolved. The latest development came on October 14, when the administrative law judge directed the DEA to respond to a request to reopen the hearing for limited additional testimony and discovery. The agency's response is due October 21.
For anyone following the process, it's important to distinguish rescheduling from legalization. Moving marijuana to Schedule III would be a significant federal policy change, but it would not, by itself, make marijuana federally legal for all purposes or eliminate state-level restrictions.
I also hope federal reform will make meaningful clinical research easier, improve our understanding of cannabinoids, and give us better evidence to guide patients. Cannabis isn't a one-size-fits-all treatment, and questions about dosing, formulations, drug interactions, and long-term effects deserve serious medical attention.
For now, Texas patients still need to understand the requirements of the state's Compassionate Use Program. Federal rescheduling alone would not eliminate those requirements.
I'd be interested in hearing perspectives from patients, physicians, researchers, and others following these developments.